Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>M Stanley: JD HEALTH 3Q Results Beat Strongly
Recommend 5 Positive 8 Negative 1 |
||||
|
||||
|
JD HEALTH (06618.HK) management, confident in achieving or even surpassing its 2025 annual revenue growth target of 22%, has raised its adjusted net profit target to RMB6.2 billion from around RMB5.6-5.7 billion, according to a report from Morgan Stanley. JD HEALTH's 3Q25 revenue increased by 28.7% YoY to RMB17.1 billion, 4% higher than market expectations, which Morgan Stanley attributed to strong first-party sales (primarily pharmaceuticals) and advertising revenue (mainly from nutritional and health products). Morgan Stanley gave JD HEALTH an Equalweight rating and a target price of HKD60. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
